Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Buy
58
LFST Quote, Financials, Valuation and Earnings
Last price:
$7.30
Seasonality move
:
2.38%
Day range:
$6.92 - $7.34
52-week range:
$4.64 - $9.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.28x
P/B ratio:
1.94x
Volume:
2.3M
Avg. volume:
1.8M
1-year change:
-0.14%
Market cap:
$2.8B
Revenue:
$1.1B
EPS (TTM):
-$0.26
Analysts' Opinion
-
Consensus RatingLifeStance Health Group has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, LifeStance Health Group has an estimated upside of 19.18% from its current price of $7.30.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $7.30.
Fair Value
-
According to the consensus of 0 analysts, LifeStance Health Group has 19.18% upside to fair value with a price target of -- per share.
LFST vs. S&P 500
-
Over the past 5 trading days, LifeStance Health Group has overperformed the S&P 500 by 3.88% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
LifeStance Health Group does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
LifeStance Health Group has grown year-over-year revenues for 0 quarters straight. In the most recent quarter LifeStance Health Group reported revenues of $312.7M.
Earnings Growth
-
LifeStance Health Group has grown year-over-year earnings for 0 quarters straight. In the most recent quarter LifeStance Health Group reported earnings per share of -$0.02.
Enterprise value:
3B
EV / Invested capital:
1.73x
Price / LTM sales:
2.28x
EV / EBIT:
--
EV / Revenue:
2.46x
PEG ratio (5yr expected):
--
EV / Free cash flow:
84.70x
Price / Operating cash flow:
78.56x
Enterprise value / EBITDA:
210.41x
Gross Profit (TTM):
$376.3M
Return On Assets:
-4.49%
Net Income Margin (TTM):
-7.9%
Return On Equity:
-6.64%
Return On Invested Capital:
-5.57%
Operating Margin:
0.02%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $820.2M | $1B | $1.2B | $262.9M | $312.7M | |
| Gross Profit | $228.6M | $281.5M | $376.3M | $76.2M | $100.4M | |
| Operating Income | -$277.9M | -$202.9M | -$64.9M | -$74.4M | $47K | |
| EBITDA | -$213.6M | -$124M | $14.1M | -$52.9M | $15.1M | |
| Diluted EPS | -$0.80 | -$0.52 | -$0.26 | -$0.17 | -$0.02 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $328.3M | $252.6M | $264.3M | $287M | |
| Total Assets | -- | $1.9B | $2B | $2.2B | $2.1B | |
| Current Liabilities | -- | $105.2M | $112.3M | $240.9M | $217.5M | |
| Total Liabilities | -- | $369.9M | $448.2M | $720M | $670.8M | |
| Total Equity | -- | $1.5B | $1.5B | $1.5B | $1.4B | |
| Total Debt | -- | $157.4M | $212M | $251M | $279.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $47.5M | $2.2M | $61.7M | -$25.4M | $22.7M | |
| Cash From Investing | -$188.7M | -$79.2M | -$26.7M | -$9.8M | -$5.1M | |
| Cash From Financing | $19.4M | $29.3M | $25M | -$1.8M | -$2M | |
| Free Cash Flow | -$60M | -$37.3M | $35.1M | -$35.2M | $17.7M | |
LFST
Sector
Market Cap
$2.8B
$44.6M
Price % of 52-Week High
79.35%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
-0.14%
-29.09%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$7.28
200-day SMA
Buy
Level
$6.38
Bollinger Bands (100)
Buy
Level
6.2 - 7.38
Chaikin Money Flow
Sell
Level
-6.9M
20-day SMA
Sell
Level
$7.36
Relative Strength Index (RSI14)
Buy
Level
50.59
ADX Line
Sell
Level
13.78
Williams %R
Neutral
Level
-56.7926
50-day SMA
Buy
Level
$7.20
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Sell
Level
-32.8M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.3311)
Buy
CA Score
(Annual)
Level (0.2015)
Buy
Beneish M-Score
(Annual)
Level (-2.7337)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-0.0199)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
LifeStance Health Group Inc is a mental healthcare company focused on providing evidence-based, medically driven treatment services for children, adolescents, and adults suffering from a variety of mental health issues in an outpatient care setting, both in-person and through its digital health telemedicine offering.
Stock Forecast FAQ
In the current month, LFST has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The LFST average analyst price target in the past 3 months is --.
-
Where Will LifeStance Health Group Stock Be In 1 Year?
According to analysts, the consensus estimate is that LifeStance Health Group share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About LifeStance Health Group?
Analysts are divided on their view about LifeStance Health Group share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that LifeStance Health Group is a Sell and believe this share price will drop from its current level to --.
-
What Is LifeStance Health Group's Price Target?
The price target for LifeStance Health Group over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is LFST A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for LifeStance Health Group is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LFST?
You can purchase shares of LifeStance Health Group via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase LifeStance Health Group shares.
-
What Is The LifeStance Health Group Share Price Today?
LifeStance Health Group was last trading at $7.30 per share. This represents the most recent stock quote for LifeStance Health Group. Yesterday, LifeStance Health Group closed at $7.30 per share.
-
How To Buy LifeStance Health Group Stock Online?
In order to purchase LifeStance Health Group stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
